Clinical trial · Interventional
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies
NCT00038025CI-TRIAL-00035832completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Cutaneous T-cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Peripheral T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Deoxycoformycin (DCF) | Drug | Pentostatin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Deoxycoformycin (DCF)/Pentostatin
- interventionNames
- Drug: Deoxycoformycin (DCF)
Primary outcomes (1)
- measure
- Number of Participants with Overall Response
- timeFrame
- Baseline and approximately every 3 weeks thereafter
- description
- Overall responses (OR) of participants with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin defined as Complete Response (CR) and Partial Response (PR).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy. * No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy. * Life expectancy of at least 12 weeks. * Performance status equal to or less than Zubrod 2. * Signed informed consent. * Patients with measurable disease. * Age at least 16 years. * Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000. * Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal. * Adequate renal function defined as serum creatine less than or equal to 1.5 mg %. Exclusion Criteria: * No serious intercurrent illness. * Adequate contraception (if applicable). * NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV. * NO experimental clinical trial within 3 weeks of study entry. * NO patients with active CNS disease. * Full recovery from any prior surgical treatment. * NO active active infections.
References
Publications (0)
Data not yet available
No reference posted for this study.